Klinické štúdie Obézita v štáte Oklahoma
21 štúdií pre Obézita hľadá účastníkov v zariadeniach v štáte Oklahoma.
Mestá v štáte Oklahoma
Oficiálny text štúdie (anglicky)
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Children's Physicians OU, Oklahoma City
Prebieha náborFáza 3
Vek 8 až 18 · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07253285Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- Lynn Health Science Institute, Oklahoma City
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Lynn Institute of Norman, Norman
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07720271A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- University of Oklahoma Health Sciences Center, Oklahoma City
Prebieha náborFáza 3
Vek 6 až 17 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06672549Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Central States Research, Tulsa
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- South Oklahoma Heart Research, Oklahoma City
Prebieha náborFáza 3
Vek 18 až 99 · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lynn Institute of Norman, Norman
- Lynn Health Science Institute, Oklahoma City
- Essential Medical Research, Tulsa
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Alliance for Multispecialty Research, LLC, Norman
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Delricht Research of Tulsa Clinical Trials, Tulsa
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Moore
- ACCOMPLISH-2 Research Site, Tulsa
- ACCOMPLISH-2 Research Site, Yukon
Prebieha náborFáza 3Vítaní zdravých dobrovoľníkov
Vek 18 až 79 · Všetky pohlavia · Aktualizované 11. 9. 2026 · NCT07654374Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Chickasha
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Alliance for Multispecialty Research - Norman, Norman
Prebieha náborFáza 3
Vek 18 až 99 · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Chickasha
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07284875Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Norman
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT07284979Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Epic Medical Research - Oklahoma, Chickasha
- Lynn Health Science Institute, Oklahoma City
Prebieha náborFáza 3
Vek 18 až 99 · Všetky pohlavia · Aktualizované 27. 8. 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Tulsa
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Moore
Prebieha náborFáza 3
Vek 18 až 79 · Všetky pohlavia · Aktualizované 10. 8. 2026 · NCT07654361A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- AMR Norman, Norman
- Lynn Health Science Institute, Oklahoma City
Prebieha náborFáza 2
Vek 18 až 80 · Všetky pohlavia · Aktualizované 22. 7. 2026 · NCT07477704Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- University of Oklahoma, Norman
Prebieha nábor
Vek 18 až 45 · Ženy · Aktualizované 24. 6. 2026 · NCT05124808Uterine Preservation Via Lifestyle Transformation
- University of Oklahoma, Oklahoma City
Prebieha náborFáza 2
Vek 18 a viac · Ženy · Aktualizované 20. 1. 2026 · NCT05903131Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.